Tuttiquotidiani is completely free. Every day we aggregate news from 100+ sources and generate original AI summaries for you. Help us keep the service running with a small donation, or become TQ Pro for just €1/month.

Donate now TQ Pro - 1€/mo

Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Posted on August 7, 2026
By NPR
0 Views
1 min read

In brief

Generating AI summary…

Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.